Biotinylated recombinant soluble human ACE2 (rshACE2) for COVID-19

 Biotinylated recombinant soluble human ACE2 (rshACE2) has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 200+ treatments. We have not reviewed biotinylated recombinant soluble human ACE2 (rshACE2) in detail.
Mussini et al., Angiotensin Converting Enzyme 2 is a molecular decoy for targeted photodynamic SARS-CoV-2 inactivation, International Journal of Biological Macromolecules, doi:10.1016/j.ijbiomac.2025.146128